Hopkins, A. L. & Groom, C. R. The druggable genome. Nat. Rev. Drug Discov. 1, 727–730 (2002).
Article CAS PubMed Google Scholar
Uhlén, M. et al. Tissue-based map of the human proteome. Science 347, 1260419 (2015).
Churcher, I. Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones? J. Med. Chem. 61, 444–452 (2018).
Article CAS PubMed Google Scholar
Maple, H. J., Clayden, N., Baron, A., Stacey, C. & Felix, R. Developing degraders: principles and perspectives on design and chemical space. MedChemComm 10, 1755–1764 (2019).
Article CAS PubMed Google Scholar
Pettersson, M. & Crews, C. M. Proteolysis targeting chimeras (PROTACs) — past, present and future. Drug Discov. Today Technol. 31, 15–27 (2019).
Article PubMed PubMed Central Google Scholar
Schapira, M., Calabrese, M. F., Bullock, A. N. & Crews, C. M. Targeted protein degradation: expanding the toolbox. Nat. Rev. Drug Discov. 18, 949–963 (2019).
Article CAS PubMed Google Scholar
Rambacher, K. M., Calabrese, M. F. & Yamaguchi, M. Perspectives on the development of first-in-class protein degraders. Future Med. Chem. 13, 1203–1226 (2021).
Article CAS PubMed Google Scholar
Alabi, S. B. & Crews, C. M. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs. J. Biol. Chem. 296, 100647 (2021).
Article CAS PubMed PubMed Central Google Scholar
Békés, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181–200 (2022).
Article PubMed PubMed Central Google Scholar
Sakamoto, K. M. et al. Protacs: chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation. Proc. Natl Acad. Sci. USA 98, 8554–8559 (2001).
Article CAS PubMed PubMed Central Google Scholar
Okuhira, K. et al. Specific degradation of CRABP-II via cIAP1-mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein. FEBS Lett. 585, 1147–1152 (2011).
Article CAS PubMed Google Scholar
Banik, S. M. et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 584, 291–297 (2020).
Article CAS PubMed PubMed Central Google Scholar
Ahn, G. et al. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nat. Chem. Biol. 17, 937–946 (2021).
Article CAS PubMed PubMed Central Google Scholar
Lin, J. et al. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins. Theranostics 11, 8337–8349 (2021).
Article CAS PubMed PubMed Central Google Scholar
Samarasinghe, K. T. G. et al. Targeted degradation of transcription factors by TRAFTACs: TRAnscription Factor TArgeting Chimeras. Cell Chem. Biol. 28, 648–661 (2021).
Article CAS PubMed PubMed Central Google Scholar
Bondeson, D. P. et al. Lessons in PROTAC design from selective degradation with a promiscuous warhead. Cell Chem. Biol. 25, 78–87.e5 (2018).
Article CAS PubMed Google Scholar
Gadd, M. S. et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat. Chem. Biol. 13, 514–521 (2017).
Article CAS PubMed PubMed Central Google Scholar
Cantrill, C. et al. Fundamental aspects of DMPK optimization of targeted protein degraders. Drug. Discov. Today 25, 969–982 (2020).
Article CAS PubMed Google Scholar
Liu, X. et al. Assays and technologies for developing proteolysis targeting chimera degraders. Future Med. Chem. 12, 1155–1179 (2020).
CAS PubMed PubMed Central Google Scholar
Pike, A., Williamson, B., Harlfinger, S., Martin, S. & McGinnity, D. F. Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective. Drug Discov. Today 25, 1793–1800 (2020).
Article CAS PubMed Google Scholar
Rodriguez-Rivera, F. P. & Levi, S. M. Unifying catalysis framework to dissect proteasomal degradation paradigms. ACS Cent. Sci. 7, 1117–1125 (2021).
Article CAS PubMed PubMed Central Google Scholar
Farnaby, W. et al. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat. Chem. Biol. 15, 672–680 (2019).
Article CAS PubMed PubMed Central Google Scholar
Iconomou, M. & Saunders, D. N. Systematic approaches to identify E3 ligase substrates. Biochemical J. 473, 4083–4101 (2016).
Khan, S. et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat. Med. 25, 1938–1947 (2019).
Article CAS PubMed PubMed Central Google Scholar
Troup, R. I., Fallan, C. & Baud, M. G. J. Current strategies for the design of PROTAC linkers: a critical review. Explor. Target. Antitumor Ther. 1, 273–312 (2020).
Article PubMed PubMed Central Google Scholar
Morgan, P. et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Discov. Today 17, 419–424 (2012).
Article CAS PubMed Google Scholar
Bartlett, D. W. & Gilbert, A. M. A kinetic proofreading model for bispecific protein degraders. J. Pharmacokinet. Pharmacodyn. 48, 149–163 (2021).
Article CAS PubMed Google Scholar
Bartlett, D. W. & Gilbert, A. M. Translational PK–PD for targeted protein degradation. Chem. Soc. Rev. 51, 3477–3486 (2022).
Article CAS PubMed Google Scholar
Nowak, R. P. & Jones, L. H. Target validation using PROTACs: applying the four pillars framework. SLAS Discov. 26, 474–483 (2021).
Article CAS PubMed Google Scholar
Edmondson, S. D., Yang, B. & Fallan, C. Proteolysis targeting chimeras (PROTACs) in ‘beyond rule-of-five’ chemical space: recent progress and future challenges. Bioorg. Med. Chem. Lett. 29, 1555–1564 (2019).
Article CAS PubMed Google Scholar
Shultz, M. D. Two decades under the influence of the rule of five and the changing properties of approved oral drugs. J. Med. Chem. 62, 1701–1714 (2019).
Article CAS PubMed Google Scholar
Ermondi, G., Vallaro, M. & Caron, G. Degraders early developability assessment: face-to-face with molecular properties. Drug Discov. Today 25, 1585–1591 (2020).
Article CAS PubMed Google Scholar
Ermondi, G., Vallaro, M., Goetz, G., Shalaeva, M. & Caron, G. Updating the portfolio of physicochemical descriptors related to permeability in the beyond the Rule of 5 chemical space. Eur. J. Pharm. Sci. 146, 105274 (2020).
Article CAS PubMed Google Scholar
Rossi Sebastiano, M. et al. Impact of dynamically exposed polarity on permeability and solubility of chameleonic drugs beyond the Rule of 5. J. Med. Chem. 61, 4189–4202 (2018).
Article CAS PubMed Google Scholar
Klein, V. G. et al. Understanding and improving the membrane permeability of VH032-based PROTACs. ACS Med. Chem. Lett. 11, 1732–1738 (2020).
Article CAS PubMed PubMed Central Google Scholar
Atilaw, Y. et al. Solution conformations shed light on PROTAC cell permeability. ACS Med. Chem. Lett. 12, 107–114 (2021).
Article CAS PubMed Google Scholar
Kofink, C. et al. A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo. Nat. Commun. 13, 5969 (2022).
留言 (0)